EyePoint Pharmaceuticals Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- EyePoint Pharmaceuticals's estimated annual revenue is currently $3M per year.
- EyePoint Pharmaceuticals received $60.0M in venture funding in February 2019.
- EyePoint Pharmaceuticals's estimated revenue per employee is $14,658
- EyePoint Pharmaceuticals's total funding is $86M.
- EyePoint Pharmaceuticals has 202 Employees.
- EyePoint Pharmaceuticals grew their employee count by 80% last year.
- EyePoint Pharmaceuticals currently has 2 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$89.4M||577||N/A||N/A|
What Is EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products. As a leading provider of miniaturized, sustained-release drug delivery products, we focus on improving the lives of patients with serious eye disorders in indications with high unmet medical need. With 3 FDA-approved sustained release treatments in ophthalmology we continue to push the evolution of our Durasert Technology platform to further enhance treatments for wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Mark Schimpf||Head Of Sales Operations|
|Chris Fasanello||Field Reimbursement Manager|
|Claudette Galvez||Senior Quality Assurance Manager|
|Jack Weet||Senior Vice President, Regulatory Affairs And Quality|
|Naomi Noriega||Key Account Manager|
|Tom Bonk||National Business Director, Amplity Health|
|Juan Hernandez||Key Account Manager|
|Josh Stults||Surgical Key Account Manager - Dexycu|
|Matt Burton||Key Account Manager|
|Carrie Donnelly||Key Account Manager|
EyePoint Pharmaceuticals News
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting ...
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the target of a significant increase in short interest during the month of July. As of July 31st, ...
On its latest session, EyePoint Pharmaceuticals, Inc. ($EYPT) opened at 1.45, reaching a high of 1.55 and a low of 1.43 before closing at a ...
EyePoint Pharmaceuticals Funding
|2011-01-20||$10.8M||Undisclosed||Rodman & Renshaw LLC||Article|
|2012-08-03||$5.4M||Undisclosed||Rodman & Renshaw LLC||Article|
|2019-02-14||$60.0M||Undisclosed||CR Group L.P.||Article|
EyePoint Pharmaceuticals Executive Hires
|2018-11-28||Ron Honig||SVP General Counsel & Company Secretary||Article|